Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world adoption of 3 months of adjuvant oxaliplatin chemotherapy in patients with stage III colorectal cancer (CRC).
Authors
Tharani Krishnan
BC Cancer - Vancouver, Vancouver, BC, Canada
Tharani Krishnan , Joao Paulo Solar Vasconcelos , Howard J Lim , Jonathan M. Loree , Janine Marie Davies , Karamjit Gill , Sharlene Gill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 83)
DOI
10.1200/JCO.2024.42.3_suppl.83
Abstract #
83
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.
First Author: In Gyu Hwang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of adjuvant fluoropyrimidine with or without oxaliplatin therapy in older adults with mismatch repair deficient stage III colorectal cancer.
First Author: Jerod J Sears
Poster
2022 ASCO Annual Meeting
Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.
First Author: Romain Cohen
Poster
2021 ASCO Annual Meeting
Real-world survival outcomes associated with completion of adjuvant chemotherapy for stage III colon cancer.
First Author: Jemma Megan Boyle